Publication not explained

This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.

If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.

Featured Image

Read the Original

This page is a summary of: Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry, Journal for ImmunoTherapy of Cancer, February 2025, BMJ,
DOI: 10.1136/jitc-2024-010674.
You can read the full text:

Read

Contributors

The following have contributed to this page